Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7779]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
Highlights in SCLC from ESMO 2018
Dr Noemi Reguart - University of Barcelona, Barcelona, Spain
Highlights in SCLC from ESMO 2018 ( Dr Noemi Reguart - University of Barcelona, Barcelona, Spain )
26 Oct 2018
Safety analysis of entrectinib for NTRK fusion tumours
Dr George D. Demetri - Harvard Cancer Center, Boston, USA
Safety analysis of entrectinib for NTRK fusion tumours ( Dr George D. Demetri - Harvard Cancer Center, Boston, USA )
26 Oct 2018
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer ( Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA )
26 Oct 2018
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )
26 Oct 2018
Lung highlights from ESMO 2018
Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy
Lung highlights from ESMO 2018 ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )
26 Oct 2018
Erlotinib for neoadjuvant treatment of EGFR NSCLC
Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical...
Erlotinib for neoadjuvant treatment of EGFR NSCLC ( Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China )
26 Oct 2018
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...
Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )
25 Oct 2018
20 year followup on high-dose chemo with HSCT in high-risk breast cancer
Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands
20 year followup on high-dose chemo with HSCT in high-risk breast cancer ( Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands )
25 Oct 2018
Opportunities for biosimilars in practice and education
Prof Diana Lüftner- Humboldt University, Berlin, Germany
Opportunities for biosimilars in practice and education ( Prof Diana Lüftner- Humboldt University, Berlin, Germany )
25 Oct 2018
The standard of care and progress so far with PARP inhibitors for ovarian cancer
Dr Susana Banerjee - The Institute of Cancer Research, London, UK
The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )
25 Oct 2018
Ceritinib and ribociclib in ALK-positive NSCLC
Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...
Ceritinib and ribociclib in ALK-positive NSCLC ( Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
24 Oct 2018
Updates from the EMBRACA trial for advanced breast cancer
Prof Hope Rugo - University of California, San Francisco, USA
Updates from the EMBRACA trial for advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
24 Oct 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation